FR2423223A1 - Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique - Google Patents

Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique

Info

Publication number
FR2423223A1
FR2423223A1 FR7815458A FR7815458A FR2423223A1 FR 2423223 A1 FR2423223 A1 FR 2423223A1 FR 7815458 A FR7815458 A FR 7815458A FR 7815458 A FR7815458 A FR 7815458A FR 2423223 A1 FR2423223 A1 FR 2423223A1
Authority
FR
France
Prior art keywords
vaccine
immunotherapy
neoplastic disease
triphosphate
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7815458A
Other languages
English (en)
Other versions
FR2423223B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAC COLLESTER DUNCAN
Original Assignee
MAC COLLESTER DUNCAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAC COLLESTER DUNCAN filed Critical MAC COLLESTER DUNCAN
Publication of FR2423223A1 publication Critical patent/FR2423223A1/fr
Application granted granted Critical
Publication of FR2423223B1 publication Critical patent/FR2423223B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention décrit un vaccin et une dose à injecter pour l'immunothérapie d'une maladie néoplasique. On prélève chirurgicalement sur le patient à traiter un peu de tissu cancéreux qu'on désagrège ; on met les cellules en suspension dans de l'eau et l'on soumet à une turbulence hydrodynamique pour les rompre. Puis l'on mélange cette matiere, contenant de l'antigène spécifique du cancer, avec une source de Mn **+**+ (phosphate manganeux,par exemple) et éventuellement avec un gel de triphosphate (par exemple triphosphate de manganèse) pour produire le vaccin. L'inoculation de ce vaccin stimule la réaction immunitaire du patient et favorise la régression du cancer.
FR7815458A 1978-04-20 1978-05-24 Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique Granted FR2423223A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89812278A 1978-04-20 1978-04-20

Publications (2)

Publication Number Publication Date
FR2423223A1 true FR2423223A1 (fr) 1979-11-16
FR2423223B1 FR2423223B1 (fr) 1983-07-29

Family

ID=25408978

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7815458A Granted FR2423223A1 (fr) 1978-04-20 1978-05-24 Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique

Country Status (11)

Country Link
JP (1) JPS54154506A (fr)
AU (1) AU519008B2 (fr)
BE (1) BE867410A (fr)
DE (1) DE2822731A1 (fr)
FR (1) FR2423223A1 (fr)
GB (1) GB1603597A (fr)
IE (1) IE47736B1 (fr)
IN (1) IN149012B (fr)
MX (1) MX5759E (fr)
NL (1) NL7805501A (fr)
PH (1) PH14990A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132281A2 (fr) * 1983-06-10 1985-01-30 Richard F. Martin Procédé d'isolement d'antigènes membranaires de cellules

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8321009D0 (en) * 1983-08-04 1983-09-07 New R R C Immunological compositions
DE19519492A1 (de) * 1995-05-27 1996-11-28 Miele & Cie Tragvorrichtung für metallische Werkstücke
CN1100569C (zh) * 1997-01-24 2003-02-05 石桂秀 肿瘤疫苗制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617865A1 (de) * 1966-03-12 1971-09-02 Karl Dr Med Theurer Verfahren zur Herstellung von Arzneimitteln gegen Krebs
FR2081446A1 (fr) * 1970-01-21 1971-12-03 Anvar
ZA782613B (en) * 1978-05-08 1979-12-27 D Mccollester Vaccine and method for immunotherapy of neoplastic disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065141A (en) * 1960-08-24 1962-11-20 Albert E Gessler Separation of nucleoproteins and nucleic acids from aqueous protein mixtures
GB1193378A (en) * 1967-04-11 1970-05-28 Rand Dev Corp Cancer Antigen Complexes
US4053586A (en) * 1971-10-08 1977-10-11 Intermountain Laboratories, Inc. Preparation for treating squamous cell carcinoma and method for making same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617865A1 (de) * 1966-03-12 1971-09-02 Karl Dr Med Theurer Verfahren zur Herstellung von Arzneimitteln gegen Krebs
FR2081446A1 (fr) * 1970-01-21 1971-12-03 Anvar
ZA782613B (en) * 1978-05-08 1979-12-27 D Mccollester Vaccine and method for immunotherapy of neoplastic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1980 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132281A2 (fr) * 1983-06-10 1985-01-30 Richard F. Martin Procédé d'isolement d'antigènes membranaires de cellules
EP0132281A3 (fr) * 1983-06-10 1986-12-10 Richard F. Martin Procédé d'isolement d'antigènes membranaires de cellules

Also Published As

Publication number Publication date
PH14990A (en) 1982-03-12
NL7805501A (nl) 1979-10-23
JPS54154506A (en) 1979-12-05
AU3605978A (en) 1979-11-15
IN149012B (fr) 1981-08-15
IE47736B1 (en) 1984-06-13
MX5759E (es) 1984-06-28
AU519008B2 (en) 1981-11-05
BE867410A (fr) 1978-11-24
GB1603597A (en) 1981-11-25
IE780974L (en) 1979-10-20
FR2423223B1 (fr) 1983-07-29
DE2822731A1 (de) 1979-10-31

Similar Documents

Publication Publication Date Title
FR2527443B1 (fr) Composition contenant de l'endotoxine raffinee et medicament la contenant
GB1531762A (en) Cancer antigen cancer therapy and cancer diagnosis
EA200200517A1 (ru) Клеточная везикула, называемая "экзосома", ее получение и применение для стимуляции иммунного ответа
Sharpey-Schafer et al. The action of animal extracts on milk secretion
DE3789082T2 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
JPS5549393A (en) Novel tissue protein pp8
DE68921979T2 (de) Antikörper für die antilymphozyten-antikörpertherapie.
FR2423223A1 (fr) Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
DE3432714A1 (de) Tumortherapeutikum und verfahren zu seiner herstellung
Laroye How efficient is immunological surveillance against cancer and why does it fail?
Hellström et al. Newer concepts of cancer of the colon and rectum: Cellular immunity to human colonic carcinomas
DE3776561D1 (de) Verwendung von petasites-extrakten zur herstellung eines arzneimittels zur behandlung von gastrointestinalen erkrankungen.
Fisher et al. Local factors affecting tumor growth: I. Effect of tissue homogenates
GB1404225A (en) Extraction of physiologically active substrates from parathyroid
ZA722837B (en) Procedure for enzymatic scission of "natural penicillins and for enzymatic syntnesis of"semisynthetic"penicillins by means of an insoluble acilase and for enzymatic sciccion having similar therapeutic properties
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
Dipersio Regional growth differences of human tumour xenografts in nude mice
Wood ANIMAL TUMORS AS THERAPEUTIC REAGENTS
ES397459A1 (es) Procedimiento y aparato para la extraccion de sustancias terapeuticas de tejidos del bazo.
Hayashi et al. Double-label immunochemical analysis of T-cell activation markers and MHC expression in active multiple sclerosis lesions
Astwood et al. The Pigmentary Response in Phoxinus Laevis: The Effect of Blood from a Patient with Melanosarcoma
ES436866A1 (es) Procedimiento para la preparacion de antigenos.

Legal Events

Date Code Title Description
ST Notification of lapse